Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chroma Therapeutics has reported positive data from a Phase I study with its oral, once-daily experimental cancer therapy CHR-2797 in the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes and multiple myelomas who have failed on, or who are unsuitable for, chemotherapy.
Subscribe to our email newsletter
The results demonstrated that out of 13 acute myeloid leukemia (AML) patients treated in this study, three showed a complete response and one further AML patient became transfusion-independent; one multiple myelomas (MM) patient (out of two treated in this study) remained in stable disease after six months of treatment with CHR-2797; and the drug was very well-tolerated during the study.
Chroma is currently assessing CHR-2797 in AML and myelodysplastic syndrome patients in the Phase II portion of this trial. This trial is now fully recruited and results are expected in the first half of 2008.
Ian Nicholson, CEO of Chroma, said: “We are very encouraged by the efficacy we have seen in this Phase I study and look forward to further exploring how patients with this debilitating disease might be treated with CHR-2797.”